The disagreement between legendary corporate raider Carl Icahn and the directors of sequencing technology-developer Illumina has reached a head.
On 8 May the company issued a letter addressed to all Illumina shareholders, defending its stance against Icahn’s plans to shake up Illumina’s board. Icahn’s plan would “detract from...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?